Abstract
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a standard of care for patients with advanced EGFR mutated non-small cell lung cancer (NSCLC). In Thailand, gefitinib has been approved for reimbursement under the Civil Servant Medical Benefit Scheme (CSMBS) for the treatment in these patients. Therefore, this retrospective cohort study examined the patient characteristics and clinical outcomes of Thai patients with EGFR-mutated NSCLC in a real-world setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
